About Luuk van Dijk, PhD

Luuk van Dijk is a biomedical scientist from the Netherlands. He did a Master's programme in Regenerative Medicine and Technology, a collaborative programme between Utrecht University, the University Medical Center Utrecht (UMCU) and the Faculty of Biomedical Engineering at Eindhoven University of Technology (TU/e). During this programme, Luuk performed research focusing on tissue engineering of pre-vascularized bone tissue analogs, and a project on stem cell encapsulation in hydrogels for potential new therapeutic applications. After obtaining his postgraduate, he started his PhD project to investigate osteoinductive calcium phosphate ceramics for bone regeneration at the University Medical Center of Utrecht. Luuk's research focused on pre-clinical and clinical evaluation of osteoinductive calcium phosphates, which included investigation of bone grafts in in vitro studies, in clinically relevant animal models, and a clinical trial at the University Medical Center Utrecht. Since January 2021, Luuk works as Scientific Affairs Manager at Kuros Biosciences. In this role, he is responsible for medical education, scientific communications and scientific support for the various departments within the company.

About Kuros Biosciences

Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOs, is a unique synthetic bone graft that has already been used successfully across three continents and in over 10,000 spinal fusion surgeries. The next candidate in the Kuros pipeline is Fibrin-PTH – the first drug-biologic combination for interbody spinal fusions, currently undergoing a Phase 2 clinical trial in the U.S. For more information on the company, its products and pipeline, visit kurosbio.com.